A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model

Journal of Biological Chemistry

Volumn 289, Issue 18, 2014, Pages 12457-12466

  Ma, Li ^a   Gong, Haiyan ^a   Zhu, Haiyan ^a   Ji, Qing ^a   Su, Pei ^a   Liu, Peng ^a   Cao, Shannan ^a   Yao, Jianfeng ^a   Jiang, Linlin ^a   Han, Mingzhe ^a   Ma, Xiaotong ^a   Xiong, Dongsheng ^a   Luo, Hongbo R ^b   Wang, Fei ^c   Zhou, Jiaxi ^a   Xu, Yuanfu ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b Department of Pathology Joint Program in Transfusion Medicine Department of Laboratory Medicine ^*  (United States)

^c UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSIS;

BIOMACROMOLECULES; COMPUTER-AIDED DRUG DESIGN; FUNCTIONAL ASSAYS; MOUSE MODELS; SMALL MOLECULES; SMALL-MOLECULE INHIBITORS; TUMOR NECROSIS FACTORS; VIRTUAL SCREENING;

MOLECULES;

C 87; ETANERCEPT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ASSAY; COMPUTER AIDED DESIGN; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HEPATITIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

CELL DEATH; CELL SIGNALING; COMPUTER MODELING; INFLAMMATION; SMALL MOLECULES; SURFACE PLASMON RESONANCE (SPR); TUMOR NECROSIS FACTOR (TNF);

ANIMALS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS, ANIMAL; HL-60 CELLS; HUMANS; HYDRAZONES; INFLAMMATION; JURKAT CELLS; K562 CELLS; MAP KINASE KINASE 4; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899741258     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.521708     Document Type: Article

References (40)

1. Aggarwal, B. B. (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3, 745-756
2. Varfolomeev, E. E., and Ashkenazi, A. (2004) Tumor necrosis factor: an apoptosis JuNKie? Cell 116, 491-497
3. Wang, L., Du, F., and Wang, X. (2008) TNF-k induces two distinct caspase-8 activation pathways. Cell 133, 693-703
4. Aggarwal, B. B., Eessalu, T. E., and Hass, P. E. (1985) Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature 318, 665-667
5. Wajant, H., Pfizenmaier, K., and Scheurich, P. (2003) Tumor necrosis factor signaling. Cell Death Differ. 10, 45-65
6. Bradley, J. R. (2008) TNF-mediated inflammatory disease. J. Pathol. 214, 149-160
7. Feldmann, M., and Maini, R. N. (2003) Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. 9, 1245-1250
8. Shibata, H., Yoshioka, Y., Ohkawa, A., Minowa, K., Mukai, Y., Abe, Y., Taniai, M., Nomura, T., Kayamuro, H., Nabeshi, H., Sugita, T., Imai, S., Nagano, K., Yoshikawa, T., Fujita, T., Nakagawa, S., Yamamoto, A., Ohta, T., Hayakawa, T., Mayumi, T., Vandenabeele, P., Aggarwal, B. B., Nakamura, T., Yamagata, Y., Tsunoda, S., Kamada, H., and Tsutsumi, Y. (2008) Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-β antagonist. J. Biol. Chem. 283, 998-1007
9. Nam, J., and Emery, P. (2010) Aspects of TNF inhibitor therapy in rheumatoid arthritis. Mod. Rheumatol. 20, 325-330
10. Rubbert-Roth, A., and Finckh, A. (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther. 11, S1
11. Esposito, E., and Cuzzocrea, S. (2009) TNF-k as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr. Med. Chem. 16, 3152-3167
12. Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., and Tak, P. P. (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117, 244-279
13. Simsek, I. (2010) TNF inhibitors-new and old agents for rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 68, 204-210
14. Goldbach-Mansky, R., and Lipsky, P. E. (2003) New concepts in the treatment of rheumatoid arthritis. Annu. Rev. Med. 54, 197-216
15. Hasegawa, A., Takasaki, W., Greene, M. I., and Murali, R. (2001) Modifying TNFα for therapeutic use: a perspective on the TNF receptor system. Mini Rev. Med. Chem. 1, 5-16
16. Banner, D. W., D'Arcy, A., Janes, W., Gentz, R., Schoenfeld, H. J., Broger, C., Loetscher, H., and Lesslauer, W. (1993) Crystal structure of the soluble human 55 kdTNFreceptor-humanTNFα complex: implications forTNF receptor activation. Cell 73, 431-445
17. Eck, M. J., and Sprang, S. R. (1989) The structure of tumor necrosis factor-β at 2.6 A resolution: implications for receptor binding. J. Biol. Chem. 264, 17595-17605
18. Idriss, H. T., and Naismith, J. H. (2000) TNFα and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. 50, 184-195
19. Takasaki, W., Kajino, Y., Kajino, K., Murali, R., and Greene, M. I. (1997) Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNFα binding to its receptor. Nat. Biotechnol. 15, 1266-1270
20. Saito, H., Kojima, T., Takahashi, M., Horne, W. C., Baron, R., Amagasa, T., Ohya, K., and Aoki, K. (2007) A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum. 56, 1164-1174
21. Kubinyi, H. (1999) Chance favors the prepared mind-from serendipity to rational drug design. J. Recept. Signal Transduct. Res. 19, 15-39
22. Talele, T. T., Khedkar, S. A., and Rigby, A. C. (2010) Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr. Top. Med. Chem. 10, 127-141
23. Faustman, D., and Davis, M. (2010) TNF receptor 2 pathway: drug target for autoimmune diseases. Nat. Rev. Drug Discov. 9, 482-493
24. Van Herreweghe, F., Festjens, N., Declercq, W., and Vandenabeele, P. (2010) Tumor necrosis factor-mediated cell death: to break or to burst, that's the question. Cell Mol. Life Sci. 67, 1567-1579
25. Papa, S., Bubici, C., Zazzeroni, F., Pham, C. G., Kuntzen, C., Knabb, J. R., Dean, K., and Franzoso, G. (2006) The NF-kB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 13, 712-729
26. Chang, L., Kamata, H., Solinas, G., Luo, J. L., Maeda, S., Venuprasad, K., Liu, Y. C., and Karin, M. (2006) The E3 ubiquitin ligase itch couples JNK activation to TNFα-induced cell death by inducing c-FLIP(L) turnover. Cell 124, 601-613
27. Kamata, H., Honda, S., Maeda, S., Chang, L., Hirata, H., and Karin, M. (2005) Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120, 649-661
28. Karlsson, R. (2004) SPR for molecular interaction analysis: a review of emerging application areas. J. Mol. Recognit. 17, 151-161
29. Mukai, Y., Nakamura, T., Yoshikawa, M., Yoshioka, Y., Tsunoda, S., Nakagawa, S., Yamagata, Y., and Tsutsumi, Y. (2010) Solution of the structure of the TNF-TNFR2 complex. Science signaling 3, ra83
30. Vinay, D. S., and Kwon, B. S. (2011) The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases. Clin. Exp. Immunol. 164, 145-157
31. Aggarwal, B. B., Gupta, S. C., and Kim, J. H. (2012) Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119, 651-665
32. Liedtke, C., and Trautwein, C. (2012) The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer. Eur. J. Cell Biol. 91, 582-589
33. Berezov, A., Chen, J., Liu, Q., Zhang, H. T., Greene, M. I., and Murali, R. (2002) Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 277, 28330-28339
34. Rich, R. L., Hoth, L. R., Geoghegan, K. F., Brown, T. A., LeMotte, P. K., Simons, S. P., Hensley, P., and Myszka, D. G. (2002) Kinetic analysis of estrogen receptor/ligand interactions. Proc. Natl. Acad. Sci. U.S.A. 99, 8562-8567
35. Thurmond, R. L., Wadsworth, S. A., Schafer, P. H., Zivin, R. A., and Siekierka, J. J. (2001) Kinetics of small molecule inhibitor binding to p38 kinase. Eur. J. Biochem. 268, 5747-5754
36. Carter, P. H., Scherle, P. A., Muckelbauer, J. K., Voss, M. E., Liu, R. Q., Thompson, L. A., Tebben, A. J., Solomon, K. A., Lo, Y. C., Li, Z., Strzemienski, P., Yang, G., Falahatpisheh, N., Xu, M., Wu, Z., Farrow, N. A., Ramnarayan, K., Wang, J., Rideout, D., Yalamoori, V., Domaille, P., Underwood, D. J., Trzaskos, J. M., Friedman, S. M., Newton, R. C., and Decicco, C. P. (2001) Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-k. Proc. Natl. Acad. Sci. U.S.A. 98, 11879-11884
37. Davis, J. M., and Colangelo, J. (2013) Small-molecule inhibitors of the interaction between TNF and TNFR. Future Med. Chem. 5, 69-79
38. He, M. M., Smith, A. S., Oslob, J. D., Flanagan, W. M., Braisted, A. C., Whitty, A., Cancilla, M. T., Wang, J., Lugovskoy, A. A., Yoburn, J. C., Fung, A. D., Farrington, G., Eldredge, J. K., Day, E. S., Cruz, L. A., Cachero, T. G., Miller, S. K., Friedman, J. E., Choong, I. C., and Cunningham, B. C. (2005) Small-molecule inhibition of TNF-k. Science 310, 1022-1025
39. Silverstein, R. (2004) D-Galactosamine lethality model: scope and limitations. J. Endotoxin Res. 10, 147-162
40. Endo, Y., Shibazaki, M., Yamaguchi, K., Kai, K., Sugawara, S., Takada, H., Kikuchi, H., and Kumagai, K. (1999) Enhancement by galactosamine of lipopolysaccharide (LPS)-induced tumour necrosis factor production and lethality: its suppression by LPS pretreatment. Br. J. Pharmacol. 128, 5-12